You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》麥格理首予和黃醫藥(00013.HK)「跑贏大市」評級 目標價83.31元
麥格理髮表研究報告,首予和黃醫藥(00013.HK)(HCM.US)H股「跑贏大市」評級,目標價83.31元,屬生科板塊首選股之一。報告稱,和黃醫藥今年最大催化劑爲6月底香港上市及旗下藥品獲得許可。本港上市以來H股股價累升51%,美股累升19%,同期恆指則跌16%。考慮公司坐擁10億美元以上現金支持併購,該行料隨着未來新產品面世,更深厚的產品線將加強投資者信心,亦降低現時產品的政策風險。

報告稱,和黃醫藥目標2025年在中國推出9款藥品及組合,在美國推出5款。麥格理形容,未來新產品連環推出將提供催化劑,釋放價值。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account